Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Report: Speedy approvals more important to Health Canada than drug safety

By Pharmaceutical Processing | April 21, 2009

:TORONTO — Health Canada’s approach to drug regulation puts too much emphasis on speeding up drug approvals and too little on following the safety profile of drugs once they hit the market, according to a new report that criticizes drug regulation in Canada. Published by the Canadian Centre for Policy Alternatives, the report also suggests the law governing drug licensing offers too few tools to the regulatory agency. As a result, it said, Health Canada cannot compel a manufacturer to undertake additional safety studies after a drug has been approved or demand that it alter safety labels on a product. “I think that there are a lot of well-meaning people within Health Canada who are trying to do a good job. But I think that at the political level, there is not the will to directly confront the drug companies by making changes that would really make a difference,” Dr. Joel Lexchin, author of the report and a long-time critic of the pharmaceutical industry, said in an interview. The report — entitled “Drug Safety and Health Canada: Going, Going … Gone?” — suggests the public’s health may be put at risk by a policy aimed at speeding up drug approvals. It also said Health Canada has no way of gauging whether safety concerns it raises — through so-called “Dear Doctor” letters or in statements to the public — have the desired effect. Lexchin, who has long advocated for more openness in the sphere of drug regulation, criticized the department for treating too much of the data submitted by drug companies as proprietary information. “Within the Canadian drug regulatory system, democratic values such as openness, safety and objective information have been ignored as Health Canada consciously opts instead for a drug regulatory system that reflects the interests of private industry,” wrote Lexchin, who teaches in the school of health policy and management at York University in Toronto. Senior Health Canada officials acknowledged some of the shortcomings Lexchin highlighted in his piece, but strongly rebutted a number of others. Dr. Supriya Sharma, director general of the therapeutic products directorate, said she took offence to the implication in Lexchin’s article that “for whatever reason we would lower standards in favour of a drug company.” “Really from the Health Canada perspective, with the companies we have a regulator-regulatee relationship,” she said from Ottawa. “Our role is health protection first and foremost. And what we’re doing is to make sure that we do the reviews of the products to the best of our abilities for safety and efficacy and quality to make sure that when we’re looking at both the risks and the benefits of the products, that the benefits are outweighing the risks.” Sharma also refuted a suggestion in the report that her division’s funding levels are affected if drug applications aren’t processed within an established timeframe. There are performance targets for how quickly drug companies should receive decisions on drug applications, but the division’s budget is not reduced if they are not met, Sharma said. Nor does the fact that there are targets mean that a new drug is more likely to be approved, she insisted. “I think the implication seems to be that we’re rushing to a positive decision because we need to make a decision.” Dr. Marc Berthiaume, director of the marketed pharmaceutical and medical devices bureau, said Lexchin’s figures are out of date when he suggested resources devoted to drug approvals vastly outweigh those directed towards monitoring the safety of drugs once they hit the market. Staffing levels and resources devoted to post-approval safety monitoring have been tripled over the past couple of years, Berthiaume said. Sharma, Berthiaume and David Lee, director of the office of legislative and regulatory modernization, did agree that the 50-year-old Food and Drug Act doesn’t currently offer enough options when safety concerns arise. The act was to have been updated but the legislation, Bill C51, did not make it through Parliament before last fall’s election was called. The Health Canada officials acknowledged it would be useful to have the authority to compel a drug’s maker to change safety labelling. If a manufacturer resists making requested changes, the option is to cancel the drug’s marketing approval. That’s too blunt a tool for most scenarios, Berthiaume suggested. “It’s a big hammer,” said Berthiaume. “And from just a health perspective, it’s not a tool that has only good sides.” Lee’s group has been studying what regulators elsewhere are doing on these issues in the hopes of finding interim steps worth adopting. “We’ve been looking at the old 50-year-old rules and trying to bring the new thinking up to what we practise right now but don’t have the legal weight (to enforce),” he said. “I think we agree that they’re limited,” Sharma said of the existing tools, “and we would like to modernize that.”

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE